MSTN and Duchenne muscular dystrophy: Indeed, studies of myostatin inhibitor drugs against age-related sarcopenic muscle wasting are consistent with data from the DMD clinical trials and support the lack of synergy between mass and strength, as well as the poor translation of murine myostatin inhibition in clinical trials.